LEVEMIR Drug Profile

Summary for Tradename: LEVEMIR

High Confidence Patents:	39
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for LEVEMIR
Recent Clinical Trials:	See clinical trials for LEVEMIR

See drug prices for LEVEMIR

Recent Clinical Trials for LEVEMIR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Novo Nordisk A/S	Phase 1
Minneapolis Medical Research Foundation	N/A
Hennepin Healthcare Research Institute	N/A

See all LEVEMIR clinical trials

Pharmacology for LEVEMIR

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for LEVEMIR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for LEVEMIR Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2026-07-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2037-11-17	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2037-02-24	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2039-01-17	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for LEVEMIR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2036-12-20	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2038-04-27	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2032-06-01	Patent claims search
Novo Nordisk Inc.	LEVEMIR	insulin detemir	Injection	021536		2037-02-13	Patent claims search

International Patents for LEVEMIR

Country	Patent Number	Estimated Expiration
Poland	341395
Australia	2008213084
Poland	1877119
European Patent Office	1843809

Supplementary Protection Certificates for LEVEMIR

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
300160	Netherlands		PRODUCT NAME: INSULINE DETEMIRUM; NATIONAL REGISTRATION NO/DATE: EU/1/04/278/001 20040601; FIRST REGISTRATION: CH 56370 20031110
2004C/020	Belgium		PRODUCT NAME: INSULIN DETEMIR; AUTHORISATION NUMBER AND DATE: EU/1/04/278/001 20040601
PA2004005	Lithuania		PRODUCT NAME: INSULIN DETEMIR; REGISTRATION NO/DATE: EU/1/04/278/001, EU/1/04/278/002, EU/1/04/278/003, EU/1/04/278/004, EU/1/04/278/005, EU/1/04/278/006, EU/1/04/278/007, EU/1/04/278/008, EU/1/04/278/00 20040601
CA 2004 00029	Denmark		PRODUCT NAME: INSULIN DETEMIR

LEVEMIR: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

LEVEMIR (insulin detemir) is a long-acting basal insulin analogue used for managing diabetes mellitus. Its market presence is defined by patent expiries, biosimilar competition, and evolving treatment landscapes for diabetes.

What is the patent status of LEVEMIR?

The primary patents protecting LEVEMIR have expired, significantly impacting its market exclusivity. Novo Nordisk, the originator, held key patents that have lapsed in major markets. For example, the primary U.S. patent for insulin detemir expired in 2019 [1]. European patent expirations also occurred in subsequent years, paving the way for generic and biosimilar entry. The loss of patent protection allows other manufacturers to develop and market bioequivalent versions of insulin detemir.

Who are the key competitors for LEVEMIR?

Competition for LEVEMIR comes from several sources:

• Other Long-Acting Insulins:
  • LANTUS (insulin glargine) and TOUJEO (insulin glargine): Developed by Sanofi, these are direct competitors with similar therapeutic profiles and have also faced patent challenges and biosimilar competition.
  • HUMALOG (insulin lispro) and HUMULIN R (insulin recombinant human): Eli Lilly and Company's insulins, while primarily rapid-acting or short-acting, are part of the broader insulin market and represent alternative treatment options.
  • TRESIBA (insulin degludec) and RYBELSUS (oral semaglutide): Also from Novo Nordisk, these represent newer generation insulins and GLP-1 receptor agonists that offer different mechanisms of action and administration routes, posing a competitive threat through innovation.
• Biosimil Insulins: The expiration of LEVEMIR's patents has led to the development and introduction of biosimilar versions. Companies like Eli Lilly (basaglar, a biosimilar to Lantus, indirectly competing), and potentially others in various global markets, are introducing biosimil insulins. While specific LEVEMIR biosimil launches vary by region, the existence of biosimilar competition across the long-acting insulin class creates pricing pressure.
• Non-Insulin Diabetes Medications: The market also sees competition from oral antidiabetic agents and GLP-1 receptor agonists, which offer non-insulin treatment pathways for type 2 diabetes. These include drugs like metformin, SGLT2 inhibitors, and DPP-4 inhibitors.

What is the historical sales performance of LEVEMIR?

LEVEMIR was a significant revenue generator for Novo Nordisk for many years.

• Peak Sales: In its prime, LEVEMIR achieved substantial annual sales. For instance, in 2016, Novo Nordisk reported sales of DKK 11.9 billion (approximately USD 1.7 billion) for insulin detemir (including the combination product NovoLog Mix 70/30 and Levemir FlexPen) [2].
• Declining Sales: Post-patent expiry and with the introduction of newer insulins and biosimil competition, LEVEMIR's sales have experienced a decline. Novo Nordisk's financial reports indicate a decrease in sales for insulin detemir in recent years as newer products like Tresiba gain market share and pricing pressures emerge from biosimil entrants in other insulin categories. In 2022, Novo Nordisk reported DKK 4.9 billion in sales for insulin detemir, a decrease from previous years [3]. This decline reflects market dynamics including biosimilar erosion and the company's strategic shift towards newer therapies.

What are the current market trends affecting LEVEMIR?

Several market trends are currently impacting LEVEMIR:

• Biosimilarization: The ongoing introduction of biosimil insulins across the long-acting insulin class exerts downward pressure on pricing for originator products like LEVEMIR. While LEVEMIR itself may not have widespread biosimilar launches in all markets yet, the overall competitive landscape is shaped by this trend.
• Advancements in Diabetes Treatment: The development of novel oral antidiabetics and incretin mimetics (GLP-1 RAs) offers alternative treatment options for type 2 diabetes, potentially reducing reliance on insulin therapy for a segment of the patient population.
• Preference for Newer Insulin Analogues: Newer insulin analogues, such as insulin degludec (Tresiba) and insulin glargine U-300 (Toujeo), offer potential advantages in terms of pharmacokinetic profiles, such as longer duration of action and lower risk of nocturnal hypoglycemia. This leads to a gradual shift in prescribing patterns.
• Managed Care and Formulary Decisions: Payer organizations and pharmacy benefit managers increasingly favor lower-cost alternatives, including biosimil products, which can influence market access and prescription volume for older insulins.
• Geographic Market Variations: The pace of patent expiry, regulatory approval of biosimil insulins, and market adoption varies significantly across different geographic regions, impacting LEVEMIR's sales trajectory in each market.

What is the projected financial trajectory for LEVEMIR?

The financial trajectory for LEVEMIR is projected to be one of continued decline, albeit at a moderated pace depending on specific market conditions and remaining patent lifecycles for certain formulations or regions.

• Revenue Erosion: Ongoing biosimilar competition and the availability of newer, potentially more effective, or more convenient diabetes treatments will continue to erode LEVEMIR's market share and pricing power.
• Genericization: As more markets see the expiry of secondary patents and regulatory pathways for biosimil approval mature, the introduction of multiple biosimilar competitors is likely, accelerating price erosion.
• Novo Nordisk's Strategic Focus: Novo Nordisk is actively focusing its R&D and commercial efforts on newer therapeutic areas, including GLP-1 receptor agonists (e.g., Ozempic, Wegovy) and next-generation insulins. This strategic reallocation of resources may lead to less emphasis on marketing and supporting older products like LEVEMIR.
• Emerging Markets: While developed markets will likely see the most rapid decline, LEVEMIR may retain a more stable market presence in emerging economies for a longer period due to pricing sensitivities and slower adoption of newer, more expensive therapies. However, even in these markets, the eventual introduction of biosimil alternatives will impact sales.

The overall financial trajectory points towards a significant reduction in LEVEMIR's contribution to Novo Nordisk's revenue over the next five to ten years, as it transitions from a blockbuster product to a mature or legacy asset within the insulin market.

Key Takeaways

LEVEMIR's market exclusivity has ended due to patent expiries, leading to increased competition from biosimil insulins and alternative diabetes treatments. Historical sales peaked in the mid-2010s, but revenue has declined due to these competitive pressures and the introduction of newer insulin analogues. The financial trajectory for LEVEMIR is projected to be one of continued decline as biosimilarization accelerates and pharmaceutical companies prioritize newer, innovative therapies.

FAQs

1. When did the primary patents for LEVEMIR expire in major markets? The primary U.S. patent for insulin detemir expired in 2019. European patent expirations followed in subsequent years.
2. Which companies are the main competitors to LEVEMIR? Key competitors include other long-acting insulins like Lantus and Tresiba, as well as biosimilar versions of insulins and non-insulin diabetes medications such as GLP-1 receptor agonists.
3. What has been the trend in LEVEMIR's sales performance? LEVEMIR experienced peak sales in the mid-2010s, with annual revenues reaching approximately USD 1.7 billion in 2016. Sales have since declined significantly, with reported revenues of DKK 4.9 billion in 2022.
4. How is biosimilar competition affecting LEVEMIR? Biosimilarization across the long-acting insulin class creates pricing pressure and erodes market share for originator products like LEVEMIR, even if specific LEVEMIR biosimil launches are market-dependent.
5. What is the long-term financial outlook for LEVEMIR? The financial outlook for LEVEMIR is one of continued revenue decline due to ongoing biosimilar competition, the availability of newer diabetes therapies, and shifts in pharmaceutical companies' strategic priorities toward innovative treatments.

Citations

[1] U.S. Food & Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/ [2] Novo Nordisk. (2017). Annual Report 2016. [3] Novo Nordisk. (2023). Annual Report 2022.